SAVE THE DATE

Be sure to mark your calendars!

2016 Fall Meeting
Renaissance Arts Hotel in New Orleans
September 30 - October 01, 2016

More details coming soon!

Find a Psychiatrist

image

Resources for the Public

image

Calendar of Events

image

Newsletters

image

Spring Meeting Highlights


Mississippi Exec Angela Ladner with friends and members pausing for the peanut butter and jelly sandwiches and hot chocolate provided by the hotel each night!  Yummy!! 

Dr. Dean Robinson receives special thanks from the membership for two great years of service as President

Dr. Lee Stevens is given appreciation for his service as Past President

Dr.  Lee Michals receives LSU Shreveport Excellence in Psychiatry Award for Graduating Residents-Fellows

Dr. Jill McCall is awarded the Resident-Fellow LSU New Orleans Excellence in Psychiatry Award

Dr. Veronique Haymon receives the Tulane Resident-Fellow Excellence in Psychiatry Award 

Not pictured is Dr. Jason Boudreaux who received the Resident-Fellow LSU Baton Rouge Excellence in Psychiatry Award.  Congratulations to all!

Latest News

Psychiatric News Alert

The Voice of the American Psychiatric Association and the Psychiatric Community
  • FDA Approves First Medication for Psychosis Associated With Parkinson’s Disease

    The Food and Drug Administration (FDA) on Friday approved Nuplazid (pimavanserin) tablets, the first medication approved in the United States to treat psychosis in patients with Parkinson’s disease.

    Although Parkinson’s disease is recognized as a movement disorder, the disease is sometimes preceded and frequently accompanied by other cognitive and psychiatric features. Some studies suggest that up to 50% of all patients with Parkinson’s disease will experience hallucinations or delusions at some time during the course of their illness—believed to be in part due to the elevated dopamine levels produced by common Parkinson’s disease medications.

    Efforts to treat PDP with antipsychotics commonly prescribed for schizophrenia to date have proven mostly futile (PDP patients taking clozapine experienced worsening Parkinson’s disease symptoms; PDP patients taking quetiapine experienced fewer side effects, but the medication has yet to be proven to be more effective than placebo in these patients). However, pimavanserin is a selective-serotonin inverse agonist that preferentially targets 5-HT2A receptors, while avoiding activity at dopamine and other receptors commonly targeted by antipsychotics.

    The FDA’s decision to approve pimavanserin was based on the results of a trial in which adults with PDP were randomly assigned to take 40 mg of pimavanserin or placebo daily for six weeks. Patients taking pimavanserin experienced fewer and less severe hallucinations and delusions without worsening the primary motor symptoms of Parkinson’s disease. The most...